VacZine Analytics  
MarketVIEW - Chikungunya vaccines

Updated: June 2014

Chikungunya virus is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia. In some cases the virus can cause recurrent disease, neurological complications and severe neonatal disease (encephalopathy). Although CHIK is endemic in Africa/Southeast Asia, recently outbreaks have occurred in previously CHIK free countries, including China, Papua New Guinea, Laos, New Caledonia and Bhutan. The first documented outbreak of CHIK in the Americas occurred in December 2012: as of April 2014, more than 40,000 probable and confirmed cases were reported. Because there is no specific treatment for CHIK infection many institutions have considered the prospect for a prophylatic vaccine.

This MarketVIEW product is a comprehensive commercial evaluation examining the potential (value/volume) of a prophylatic Chikungunya vaccine to 2035. The prospects of the vaccine in Western travellers, endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV005 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2014 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains